WHO Director-General and WHO Civil Society Task Force on TB release a joint statement setting collective priorities in preparation for the 2023 UN High-Level Meeting on TB.

At the International AIDS Conference in Montreal, civil society and activist organizations launched a new campaign inspired by the legacy of the late Dr. Paul Farmer calling for the “staff, stuff, space, systems, and support” necessary for shorter, effective TB treatment regimens to reach all who need them as a human right by the end of 2024.

Partners announce two new agreements to lower the price of rifapentine-based treatments to prevent TB in low- and middle-income countries.

In 2021, TB CAB celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.

The World Health Organization releases the first-ever report on the pipeline of the vaccines currently in development to prevent infections caused by antimicrobial-resistant bacterial pathogens.

The World Health Organization releases updated guidelines and a new operational handbook on TB care and support to improve the quality of life and better outcomes for people with TB.

The Global Plan to End TB 2023-2030 outlines the priority actions and estimated financial resources needed to end TB as a global health threat by 2030.

Communities affected by TB everywhere have a right to benefit from scientific progress, including access to short-course, bedaquiline-based treatment regimens for drug-resistant TB.

The Global TB Caucus releases an analysis examining the region’s laws on public health, health systems, labor, TB, and other infectious diseases.

The updated WHO consolidated guidelines on treatment of drug-susceptible TB include a new recommendation for the use of a 4-month regimen composed of isoniazid, rifapentine, moxifloxacin and pyrazinamid.